Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer
A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope HER-2/Neu Peptide Vaccine in Subjects Previously Treated for HER-2 Positive Breast Cancer
Sponsor: Marker Therapeutics, Inc.
Listed as NCT01632332, this PHASE1 trial focuses on HER2-positive Breast Cancer and Male Breast Cancer and remains completed. Sponsored by Marker Therapeutics, Inc., it has been updated 8 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Nov 2018 — Feb 2019 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
▶ Show 3 earlier versions
-
Jun 2018 — Nov 2018 [monthly]
Unknown Status PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE1
First recorded
Jul 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Marker Therapeutics, Inc.
- Mayo Clinic
For direct contact, visit the study record on ClinicalTrials.gov .